Apogee Therapeutics Inc
APGE
Company Profile
Business description
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Contact
221 Crescent Street
Building 17, Suite 102b
WalthamMA02453
USAT: +1 650 394-5230
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
261
Stocks News & Analysis
stocks
ASX share’s growth story intact despite supply constraints
Short term supply challenges but Chinese growth story remains intact.
stocks
ASX healthcare giant rallies despite a fall in profits
Easing investor concerns and signalling a return to growth.
stocks
Weekly earnings wrap: BHP, CSL, NAB and more
Materials, banking, healthcare and retail heavyweights reveal diverging outlooks.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,276.40 | 7.00 | -0.08% |
| CAC 40 | 8,453.09 | 48.82 | -0.57% |
| DAX 40 | 25,983.04 | 108.29 | -0.42% |
| Dow JONES (US) | 52,759.21 | 703.84 | -1.32% |
| FTSE 100 | 10,748.16 | 4.81 | 0.04% |
| HKSE | 25,698.49 | 203.42 | 0.80% |
| NASDAQ | 26,067.17 | 263.92 | -1.00% |
| Nikkei 225 | 65,690.39 | 526.40 | -0.79% |
| NZX 50 Index | 13,935.01 | 15.19 | 0.11% |
| S&P 500 | 7,641.16 | 66.82 | -0.87% |
| S&P/ASX 200 | 9,063.70 | 2.10 | -0.02% |
| SSE Composite Index | 3,903.72 | 9.30 | 0.24% |